VISTAGEN THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.37 USD | -2.46% |
|
-2.89% | -14.98% |
Presentation Operator MessageOperator (Operator)Good day, and welcome to the VistaGen Second Q...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company focuses on transforming the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. It is advancing therapeutics for treatment of anxiety, depression, and multiple CNS disorders. Its pipeline includes six clinical-stage product candidates, including fasedienol (PH94B), itruvone (PH10), PH15, PH80, and PH284, each an investigational agent belonging to a new class of drugs known as pherines, as well as AV-101, which is an oral antagonist of the N-methyl-D-aspartate receptor (NMDAR). Pherines, which are administered as low-dose nasal sprays, are designed with a rapid-onset mechanism of action that activates chemosensory neurons in the nasal cavity and can impact key neural circuits in the brain without systemic uptake or direct activity on CNS neurons in the brain. PH94B is a synthetic investigational pherine from the androstane family.
Calendar
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
4.37
USD
Average target price
13.25
USD
Spread / Average Target
+203.20%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -14.98% | 118M | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- VTGN Stock
- News Vistagen Therapeutics, Inc.
- Transcript : VistaGen Therapeutics, Inc., Q2 2023 Earnings Call, Nov 10, 2022
